Vancouver, British Columbia – TheNewswire - August 10, 2021 - Gnomestar Craft Inc. (CSE:GNOM), (CNSX:GNOM.CN), (FSE:1JV1), (OTC:VDQSF) (“Gnomestar” or the “Company") is pleased announce it has partnered with BOAZ Pharmaceuticals Inc. dba BOAZ Craft Cannabis (“BOAZ”) to provide its craft products through the BOAZ sales channels.


BOAZ operates a state of the art 21,500 square facility that utilizes environmentally friendly grow pods – their mission is to grow the highest quality cannabis possible in an environmentally friendly way.  Through the hard work of our team at Gnomestar, we are able to compliment the production of BOAZ and include ourselves in the suite of offerings that meet the high standards of BOAZ - a top OCS certified craft cannabis producer.


Our 12,000 square foot facility continues to refine its processes to improve upon our previous successes and this agreement represents a milestone on the path of recognition for our growers and their techniques.  The first offering will be a select batch of Gnomestar’s 15 day hang dried, 45 day cold cured, hand trimmed Red Congolese.  “We look forward to an exciting combination of quality and effort that will strengthen our position in the market”, said Mark Lotz, CEO of Gnomestar.


This initial offering of Red Congolese will be available at retailers in Alberta, Saskatchewan, Manitoba, and Yukon, with a plan to bring addition unique strains to market in Q4 2021.  


About BOAZ


BOAZ Craft Cannabis a privately owned company is emerging as one of Canada’s most exciting producers and processors of Certified Craft Cannabis (OCS). Based in Calgary, Alberta, the BOAZ brand is synonymous with high quality products, with connoisseurs raving about the overall quality of BOAZ’s products, highlighting, among other things, the flavor/taste profile, smell, and intensity.


For further information please contact:

David Isaak, Chief Executive Officer and President
BOAZ Pharmaceuticals Inc. dba BOAZ Craft Cannabis

Email: disaak@boazpharm.com


About Gnomestar  


For further information please contact:

Mark Lotz, Chief Executive Officer and CFO
Vodis Pharmaceuticals Inc.

Email: mark@vodis.ca




Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.


Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws including statements relating to the outlook of the business of the Company, the planned expenditures for upgrades and other renovations at the Company’s facilities in Delta, BC. Although the Company believes considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them as the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements, depending on, among other things, the risks that the private placement financings may not close for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities) or that the terms of the private placement financing may differ from those that currently are contemplated. The statements in this news release are made as of the date of this release. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Copyright (c) 2021 TheNewswire - All rights reserved.